The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."

Condition	Treatment or Intervention	Phase
Opioid-Related Disorders	Drug: Buprenorphine	Phase II

Further Study Details: 

1) Compare subjects response to liquid vs tablet formulation 2) Assess bioequivalency of liquid vs tablet 3)Compare subject preference 4) Evaluate if dose response curve for tablet = to liquid form

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

M/F ages 18-65. Meet DMS-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Pregnant or nursing women. Acute medical condition that would interfere with study participation or put safety of subjects in jeopardy. Current daily use of anti-convulsants, antabuse or neuroleptics. DSM-IV diagnosis of ETOH or sedative/hypnotics dependence.

California
      Friends Research Institute, Los Angeles,  California,  90025,  United States

Study chairs or principal investigators

Walter Ling, M.D.,  Principal Investigator,  Friends Research Institute   

Study ID Numbers:  NIDA-10068-1; R01-10068-1
Record last reviewed:  October 1997
Last Updated:  November 18, 2004
Record first received:  September 20, 1999
ClinicalTrials.gov Identifier:  NCT00000320
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08